George Cardoza's most recent trade in Neogenomics Inc. was a trade of 839 Common Stock done . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | George A. Cardoza | President & COO, Lab Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 839 | 244,157 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | George A. Cardoza | President & COO, Lab Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2022 | 503 | 244,996 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 61,143 | 245,499 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 40,502 | 40,502 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | George A. Cardoza | President & COO, Lab Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 7,584 | 184,356 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | George A. Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 35,171 | 35,171 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | George A. Cardoza | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 6,207 | 377,109 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 24 Nov 2020 | 77,074 | 370,902 (0%) | 0% | 45.5 | 3,505,326 | Common Stock |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 24 Nov 2020 | 77,074 | 447,976 (0%) | 0% | 7.5 | 579,596 | Common Stock |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2020 | 77,074 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.52 per share. | 24 Nov 2020 | 72,926 | 423,828 (0%) | 0% | 7.5 | 548,404 | Common Stock |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2020 | 72,926 | 127,074 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | George Cardoza | President, Pharma Services | Sale of securities on an exchange or to another person at price $ 45.19 per share. | 24 Nov 2020 | 52,926 | 370,902 (0%) | 0% | 45.2 | 2,391,726 | Common Stock |